

Molecular Therapeutics of Cancer Research Conference -- 2018

Sponsored by the Cancer Molecular Therapeutics Research Association

Sundance Mountain Resort, Sundance, Utah

Schedule and Program

IMPORTANT NOTICE: By attending this conference, you agree to respect the confidentiality of the proceedings. Specifically, photographing or recording of sessions, posters or discussions is not permitted. Reference to material presented or discussed may not be included in any publication. Permission to cite information may subsequently be obtained directly from the presenter and is beyond the control of the meeting organizers.

All scientific sessions will be at the Redford Center

Breaks, Poster sessions with refreshments will be at the Redford Center

The opening reception Sunday evening will be at the Rehearsal Hall

The farewell reception will be at the Rehearsal Hall

****Lodging will be at the Sundance Mountain Resort, Sundance, Utah****

Meals will be at the Tree House (breakfast), the Redford Center (lunch/breaks) and the Rehearsal Hall (dinner and farewell reception)

SUNDAY – JULY 22

4:00 pm	Arrival and check-in
6:00 – 7:00 pm	<i>Dinner</i>
7:30 – 7:45 pm	Welcome / Introductory Comments Peter Houghton, Greehey Children’s Cancer Research Institute, San Antonio, TX, President CMTRA
7:45 – 8:45 pm	KEYNOTE SPEAKER – Robert Abraham, Sr. Vice President and Chief Scientific Officer Oncology Research Unit Pfizer Worldwide Research and Development “A New Chapter in Cancer Drug Discovery: Opportunities and Challenges”
9:00 pm –	<i>Opening reception</i>

MONDAY – JULY 23

7:30 – 8:15 am	<i>Breakfast</i>
8:30 – 12:00 pm	MORNING SESSION: “Immuno-Oncology - Small Molecule Approaches that Work by Novel Mechanisms, and the Intersection with DNA Damaging Agents” Discussion Leader: Robert Kramer
8:30 – 8:45 am	Introduction
8:45 – 9:15 am	Jack Hunt, Bristol-Myers Squibb "Small Molecule IO Drugs: IDO and Beyond"

9:15 – 9:40 am	Discussion
9:40 – 10:00 am	Coffee Break
10:00 – 10:30 am	Tom Gajewski, University of Chicago, Chicago, IL “Tumor and Host Factors Controlling Anti-Tumor Immunity and Immunotherapy Efficacy”
10:30 – 10:55 am	Discussion
11:00 – 11:30 am	Jung-Min Lee, National Cancer Institute, Bethesda, MD and Viia Valge-Archer, PhD, AstraZeneca, UK “Pre-clinical Combination of DDR Inhibition with Immune Checkpoint Inhibitors?”
11:30 – 11:55 am	Discussion
12:00 – 1:00 pm	<i>Lunch</i>
1:00 – 4:15 pm	OPEN NETWORKING AFTERNOON
4:30 – 5:45 pm	Poster Session and Social
6:00 – 6:45 pm	<i>Dinner</i>
7:00 – 9:50 pm	EVENING SESSION: “Developing Drugs with a Molecular Indication Agnostic to Cancer Type” Discussion Leader: Eli Wallace, Peloton Therapeutics, Dallas, TX, and James Winkler, FORMA Therapeutics, Watertown, MA
7:00 – 7:05 pm	Introduction
7:05 – 7:35 pm	Steven Andrews, Loxo Oncology, Stamford, CT Discovery and Development of Larotrectinib (LOXO-101), a Selective TRK Inhibitor, for Cancers Driven by TRK Fusions”
7:35 – 8:00 pm	Discussion
8:00 – 8:30 pm	Sarah Ross, AstraZeneca “AZD4785 a High-affinity Therapeutic Antisense Oligonucleotide Inhibitor of KRAS”
8:30 – 8:55 pm	Discussion
8:55 – 9:25pm	Scott Pruitt, Merck, Rahway, NJ “The First Tumor-type Agnostic Regulatory Approval: Pembrolizumab for the Treatment of Advanced MSI-H/dMMR Cancer”
9:25 – 9:50pm	Discussion
9:50 pm –	<i>Social</i>

7:30 – 8:15 am	<i>Breakfast</i>
8:30 – 12:00 pm	MORNING SESSION: “MCL1 Biology and Inhibitors in Cancer Therapy” Discussion Leader: William Placzek, University of Alabama at Birmingham, Birmingham, AL
8:30 – 8:45 am	Introduction
8:45 – 9:15 am	Anthony Letai, Dana Farber Cancer Institute, Boston, MA “Therapeutic Targeting of BCL-2 Family Proteins Guided by Mitochondria”
9:15 – 9:40 am	Discussion
9:40 – 10:00 am	<i>Coffee Break</i>
10:00 – 10:30 am	Paul Hughes, Amgen “The Discovery and Preclinical Characterization of AMG 176, a First in Class Mcl-1 Inhibitor In Clinical Development For Multiple Myeloma and AML”
10:30 – 10:55 am	Discussion
11:00 – 11:30 am	Adriana Tron, AstraZeneca “Selective Mcl-1 inhibition by AZD5991 induces on-target cell death and achieves anti-tumor activity in Multiple Myeloma and Acute Myeloid Leukemia”
11:30 – 12:00 pm	Discussion
12:00 – 1:00 pm	<i>Lunch</i>
1:00 – 4:15 pm	OPEN NETWORKING AFTERNOON
4:30 – 5:45 pm	Poster Session and Social
6:00 – 6:45 pm	<i>Dinner</i>
7:00 – 9:50 pm	EVENING SESSION: “Academic versus Industrial Drug Discovery” Discussion Leader: John Lazo, University of Virginia, Charlottesville, VA
7:00 – 7:05 pm	Introduction
7:05 – 7:35 pm	Michelle Arkin, University of California, San Francisco, CA “The Yin and Yang of Team Science”
7:35 – 8:00 pm	Discussion
8:00 – 8:30 pm	Bruce Littlefield, Eisai “A Winning Trifecta: The Industry-Academia-NCI Collaboration that Drove Discovery and Development of Eribulin (Halaven®) for Metastatic Breast Cancer”

8:30 – 8:55 pm	Discussion
8:55 – 9:25 pm	Laurence Baker, University of Michigan “An Academic Approach to Drug Discovery and Development”
9:25- 9:50 pm	Discussion
9:50 pm –	<i>Social</i>

WEDNESDAY JULY 25

7:30 – 8:15 am	<i>Breakfast</i>
8:30 – 12:00 pm	MORNING SESSION: “Fusion-Driven Sarcomas – Recent Therapeutic Advances and Remaining Challenges” Discussion Leader: Peter Houghton, Peter Houghton, Greehey Children’s Cancer Research Institute, San Antonio, TX
8:30 – 8:45 am	Introduction
8:45 – 9:15 am	Matthew McBride, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA “Genomic Hijacking of Chromatin Remodeling Complexes by Fusion Oncoproteins”
9:15 – 9:40 am	Discussion
9:40 – 10:00 am	Coffee Break
10:00 – 10:30 am	Gerard Mcgeehan, Syndax Pharma “Targeting the Menin-MLL1 Interaction Site as a Treatment for Mixed Lineage Leukemia”
10:30 – 10:55 am	Discussion
11:00 – 11:30 am	Stephen Lessnick, Nationwide Children’s Hospital, Columbus, OH “Turn on, Tune in, Drop out! LSD1 in Ewing sarcoma”
11:30 – 11:55 am	Discussion
12:00 – 1:00 pm	Lunch
2:00 – 3:00 pm	ORAL PRESENTATIONS – Four Selected Presenters from the Posters
3:00 – 5:30 pm	AFTERNOON SESSION: “Current and Emerging Therapies in Small-Cell and Non-Small-Cell Lung Cancer” Discussion Leader: Phillip Dennis, AstraZeneca
3:00 – 3:15 pm	Introduction
3:15 – 3:45 pm	Trudy Oliver, University of Utah, Salt Lake City, UT “MYC drives a molecularly and therapeutically-distinct subtype of small cell lung cancer”

3:45 -4:10 pm	Discussion
4:10 – 4:40 pm	Ross Camidge, University of Colorado, Denver, CO “The Angel and the Octopus: Competing Demands for Optimal Clinical Development of Novel NSCLC Agents”
4:45 – 5:10 pm	Discussion
6:00 – 10:00 pm	<i>Farewell Reception</i>
THURSDAY JULY 26	
10:00 am	CHECK OUT BY 10:00 AM

SPONSOR ACKNOWLEDGEMENTS

Travel grants for trainees are supported by the
American Society for Pharmacology and Experimental Therapeutics
 (Division of Cancer Pharmacology)



SPONSOR ACKNOWLEDGEMENTS (Continued)

This meeting is co-sponsored by the
Huntsman Cancer Institute

This meeting would not be possible without the generous contributions from our many
 friends and colleagues:

- 7 Hills Pharma**
- Abbvie**
- AstraZeneca**
- Bristol-Myers Squibb**
- Crown Biosciences**
- Genentech / Astellas**
- Janssen Research and Development**
- Novartis**
- Pfizer**